Edition:
United States

BioCryst Pharmaceuticals Inc (BCRX.OQ)

BCRX.OQ on NASDAQ Stock Exchange Global Select Market

6.73USD
4:00pm EDT
Change (% chg)

$1.60 (+31.19%)
Prev Close
$5.13
Open
$6.25
Day's High
$7.39
Day's Low
$6.15
Volume
4,120,943
Avg. Vol
346,440
52-wk High
$9.25
52-wk Low
$2.61

Latest Key Developments (Source: Significant Developments)

BioCryst reports additional positive results from second interim analysis of APEX-1 trial
8:00am EDT 

May 25 (Reuters) - BioCryst Pharmaceuticals Inc :BioCryst reports additional positive results from the second interim analysis of its APEX-1 trial.BioCryst Pharma - a pre-planned analysis of peripheral and abdominal attacks showed reductions in peripheral attacks of 74%, 54%, 90% compared with placebo.BioCryst Pharmaceuticals Inc says oral BCX7353 once-daily for 28 days was generally safe and well tolerated in subjects with hae.BioCryst Pharmaceuticals Inc says additionally, no significant laboratory abnormalities were observed in two lower dose groups.BioCryst Pharmaceuticals Inc - there were no serious aes and no severe aes in APEX-1 trial.BioCryst Pharmaceuticals - three subjects in bcx7353 350 mg treatment arm, two of which were previously reported, discontinued study drug before day 28.BioCryst Pharmaceuticals Inc says most common treatment-emergent adverse events were common cold and diarrhea in trial.  Full Article

BioCryst expands development of BCX7353 to explore treatment of acute HAE attacks
Wednesday, 12 Apr 2017 06:45am EDT 

BioCryst Pharmaceuticals Inc - : BioCryst expands development of BCX7353 to explore treatment of acute HAE attacks . Has received initial regulatory approvals in Europe to initiate zenith-1 exploratory clinical trial this summer .To explore if single oral doses of liquid formulation of BCX7353 could have utility in treatment of acute angioedema attacks in some patients.  Full Article

BioCryst announces Mundipharma receives approval for Mundesine in Japan
Monday, 3 Apr 2017 07:18am EDT 

Biocryst Pharmaceuticals Inc : Biocryst announces Mundipharma receives approval for Mundesine in Japan .Biocryst Pharmaceuticals Inc - Mundipharma obtained regulatory approval of Mundesine by Ministry of Health, Labor and Welfare in Japan.  Full Article

Biocryst Pharmaceuticals says public offering of 5.29 mln common shares priced at $8.50 per share
Thursday, 9 Mar 2017 08:26pm EST 

Biocryst Pharmaceuticals Inc : Biocryst pharmaceuticals prices public offering of common stock .Says public offering of 5.29 million common shares priced at $8.50 per share.  Full Article

Biocryst Pharma commences public offering of common stock
Wednesday, 8 Mar 2017 04:01pm EST 

Biocryst Pharmaceuticals Inc : Biocryst Pharmaceuticals commences public offering of common stock . Says offering to sell $45.0 million of its common stock in an underwritten public offering .Says all of shares to be sold in offering are being sold by Biocryst.  Full Article

D. E. Shaw & Co reports 5 pct passive stake in Biocryst Pharmaceuticals as of Feb 23, 2017
Monday, 6 Mar 2017 04:22pm EST 

D. E. Shaw & Co, LP:D. E. Shaw & Co, L.P. reports 5 percent passive stake in Biocryst Pharmaceuticals Inc as of Feb 23, 2017 -sec filing.  Full Article

BioCryst Pharmaceuticals Q4 loss per share $0.06
Monday, 27 Feb 2017 06:15am EST 

Biocryst Pharmaceuticals Inc : Biocryst reports fourth quarter and full year 2016 financial results . Q4 loss per share $0.06 . Q4 revenue $9.0 million versus $4.6 million . Q4 revenue view $4.1 million -- Thomson Reuters I/B/E/S . Q4 earnings per share view $-0.23 -- Thomson Reuters I/B/E/S . BioCryst Pharmaceuticals Inc - sees its 2017 operating expenses to be in range of $53 to $73 million . BioCryst Pharmaceuticals Inc - for three months ended december 31, 2016, total revenues increased to $9.0 million from $4.6 million in Q4 of 2015 .BioCryst Pharmaceuticals Inc - expects its 2017 net operating cash use to be in range of $30 to $50 million.  Full Article

Biocryst Q3 loss $0.16/shr
Monday, 7 Nov 2016 06:48am EST 

Biocryst Pharmaceuticals Inc : Biocryst reports third quarter 2016 financial results . Q3 loss per share $0.16 . Q3 revenue $7.8 million versus $11 million . Q3 revenue view $5.8 million -- Thomson Reuters I/B/E/S . Q3 earnings per share view $-0.24 -- Thomson Reuters I/B/E/S . Biocryst Pharmaceuticals Inc says continues to expect its 2016 net operating cash use to be in range of $55 to $75 million . Biocryst Pharmaceuticals Inc says revised its 2016 operating expenses outlook to be in range of $68 to $80 million . Biocryst Pharmaceuticals Inc - Biocryst continues to expect its 2016 net operating cash use to be in range of $55 to $75 million .Biocryst Pharmaceuticals - 2016 operating expenses to now be in range of $68 to $80 million, a reduction from previous forecasted range of $78 to $98 million.  Full Article

D. E. Shaw & Co L.P. reports passive stake of 5.1 pct in Biocryst Pharmaceuticals as of Aug. 11
Monday, 22 Aug 2016 04:46pm EDT 

Biocryst Pharmaceuticals Inc :D. E. Shaw & Co., L.P. reports a passive stake of 5.1 percent in Biocryst Pharmaceuticals Inc as of August 11, 2016 - Sec filing.  Full Article

Baker Brosadvisors LP'S Felix Baker reports a passive stake of 14.99 pct in Biocryst Pharmaceuticals
Wednesday, 17 Aug 2016 05:04pm EDT 

Biocryst Pharmaceuticals Inc : Baker Brosadvisors LP'S Felix Baker reports a passive stake of 14.99 pct in Biocryst Pharmaceuticals Inc - SEC filing .Baker Bros' Felix Baker's stake of about 11.1 million shares in Biocryst Pharmaceuticals includes 75,000 shares of co's common stock underlying options.  Full Article

More From Around the Web

BRIEF-BioCryst reports additional positive results from second interim analysis of APEX-1 trial

* BioCryst reports additional positive results from the second interim analysis of its APEX-1 trial